NASDAQ:ROIV Roivant Sciences Q1 2026 Earnings Report $11.31 -0.05 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.04 -0.28 (-2.43%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Roivant Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.23Beat/MissN/AOne Year Ago EPSN/ARoivant Sciences Revenue ResultsActual RevenueN/AExpected Revenue$6.92 millionBeat/MissN/AYoY Revenue GrowthN/ARoivant Sciences Announcement DetailsQuarterQ1 2026Date8/11/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Roivant Sciences Earnings HeadlinesRoivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025July 28, 2025 | globenewswire.comGoldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ RatingJuly 25, 2025 | msn.comThis Crypto Is Set to Explode in JanuaryBillions Flowing Into Crypto (Here’s Where It’s Going!) Institutional money is flooding into crypto... Discover which coins they’re buying at the Crypto Hedge Fund Summit, before prices catch up.August 2 at 2:00 AM | Crypto 101 Media (Ad)Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells $1,152,000.00 in StockJuly 25, 2025 | americanbankingnews.comRoivant Sciences Ltd. (ROIV) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.com'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five monthsJune 28, 2025 | msn.comSee More Roivant Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roivant Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roivant Sciences and other key companies, straight to your email. Email Address About Roivant SciencesRoivant Sciences (NASDAQ:ROIV), a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.View Roivant Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Palantir Technologies (8/4/2025)Vertex Pharmaceuticals (8/4/2025)Axon Enterprise (8/4/2025)MercadoLibre (8/4/2025)Williams Companies (8/4/2025)ONEOK (8/4/2025)Simon Property Group (8/4/2025)Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
